Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries.

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 24, 2023

Primary Completion Date

September 24, 2024

Study Completion Date

September 24, 2024

Conditions
Pelvic CancerAbdominal CancerSurgeryProinflammatory Cytokines
Interventions
DRUG

Lidocaine Intravenous Infusion

Patients will receive 1.5mg /kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intra-operatively.

DRUG

Lidocaine and ketamine

Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.35 mg/kg ketamine intravenously as a bolus dose, followed by intravenous infusion of 0.2 mg/kg/h using a 50cc syringe pump intra- operatively.

DRUG

lidocaine and dexmedetomidine infusion

Patients will receive same infusion regimen of lidocaine 2%; as in group L plus 0.5 μg/kg dexmedetomidine intravenously as a bolus dose, followed by intravenous infusion of 0.4 μg/kg/h using a 50cc syringe pump intra-operatively.

Trial Locations (1)

Unknown

Faculty of medicine, Alexandria

All Listed Sponsors
lead

Alexandria University

OTHER

NCT06631625 - Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries. | Biotech Hunter | Biotech Hunter